Last reviewed · How we verify

Xerava (ERAVACYCLINE DIHYDROCHLORIDE)

Tetraphase Pharms · FDA-approved approved Small molecule Quality 51/100

Xerava works by binding to the bacterial ribosome, preventing the synthesis of essential proteins necessary for bacterial survival.

Xerava (eravacycline dihydrochloride) is a small molecule antibiotic developed by Tetraphase Pharmaceuticals. It was approved by the FDA in 2018 for the treatment of complicated abdominal infections. Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to bacterial cell death. The drug is patented and has no generic manufacturers. Key safety considerations include its potential to cause gastrointestinal side effects and alterations in liver function.

At a glance

Generic nameERAVACYCLINE DIHYDROCHLORIDE
SponsorTetraphase Pharms
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved
First approval2018

Mechanism of action

Eravacycline is an antibacterial drug [see Microbiology 12.4)].

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: